Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
RO5093151 · 3 trials · 3 indications
| Arm | Type | Description |
|---|---|---|
| Placebo | PLACEBO_COMPARATOR | - |
| RO5093151 | EXPERIMENTAL | - |
| 1 Ketoconazole DDI | EXPERIMENTAL | - |
| 2 Rifampicin DDI | EXPERIMENTAL | - |
| 3 ATZ/r DDI | EXPERIMENTAL | - |
| 1 | EXPERIMENTAL | - |
| 2 | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Placebo | DRUG | Placebo to RO5093151 |
| RO5093151 | DRUG | oral doses twice daily for up to 28 days |
| atazanavir | DRUG | Multiple oral doses |
| ketoconazole | DRUG | Multiple oral doses |
| rifampicin | DRUG | Multiple oral doses |
| ritonavir | DRUG | Multiple oral doses |
Inclusion Criteria: * Adult patients, at least 21 years of age, inclusive * Diagnosis of ocular hypertension or primary open angle glaucoma in at least one eye * Able to participate and willing to give informed consent Exclusion Criteria: * Presence of extreme narrow angle with complete or partia...
RO5093151 is an investigational small molecule being studied for non-alcoholic fatty liver disease (NAFLD), ocular hypertension, and open-angle glaucoma. It has also been evaluated in healthy volunteers for drug-drug interaction studies. The compound is in clinical development by Roche Holding AG.
RO5093151 is being developed by Roche Holding AG, which trades under the ticker RHHBY. The company has sponsored clinical trials of the drug in patients with non-alcoholic fatty liver disease, ocular hypertension, and open-angle glaucoma, as well as in healthy volunteers.
RO5093151 has completed Phase 1 and Phase 2 clinical trials. A Phase 1 study in non-alcoholic fatty liver disease and a Phase 2 study in ocular hypertension or open-angle glaucoma have both been completed. The drug remains investigational and is not approved.
RO5093151 has been studied in three completed trials. NCT01277094 was a Phase 1 study in 82 patients with non-alcoholic fatty liver disease in Austria and Germany. NCT01493271 was a Phase 2 study in 31 patients with ocular hypertension or open-angle glaucoma. NCT01591850 was a Phase 1 drug-drug interaction study in 51 healthy volunteers.
RO5093151 is the sole name reported for this investigational compound. No alternative names have been associated with it in the clinical trial records. It is a small molecule developed by Roche Holding AG for metabolic and ophthalmologic conditions.